S2 5.4 – Bonus Interview with Jörn Schattenberg: What FDA webcast means for researchers and trial sites outside the US

NEW CONTENT: Prof. Dr. Jörn M. Schattenberg joins Roger Green to discuss his highly optimistic reaction to the FDA Webcast

BONUS INTERVIEW: Prof. Dr. Jörn M. Schattenberg and Roger Green spend 20 minutes discussing Joern’s reaction to the January 29 FDA Webcast. Joern discusses why digital pathology is such a benefit to trial sites outside the US and some of the new clinical development and sample size considerations emanating from a need to provide more robust safety data. An interesting, informative conversation.